Clinical Spectrum of Anti-SEZ6L2 Syndrome Authors: Juri Luis Habicht, Guido Cammá, Katharina Wurdack, Bianca Teegen, Harald Prüss, Carsten Finke Published: 2026 ABSTRACT Background and ObjectivesAnti–seizure-related 6 homolog like 2 (SEZ6L2) antibodies are a rare cause of immune-mediated cerebellar syndromes. The clinical phenotype, diagnostic features, and outcomes have not been systematically synthesized, and the evidence is limited to case reports and case series. We, therefore, aimed to (1) characterize the clinical course and longitudinal brain volumetric changes in a patient with anti-SEZ6L2 syndrome and (2) systematically review the published evidence regarding clinical features, diagnostics, treatment, and outcomes.MethodsWe performed a single-patient observational study with serial clinical assessments and cross-sectional and longitudinal MRI volumetry and compared the findings with those from age-matched and sex-matched healthy controls. In addition, we conducted a PRISMA-compliant systematic review of MEDLINE and EMBASE from 1964 to December 1, 2025, including published reports of patients with anti-SEZ6L2 antibodies. Data were synthesized descriptively, and because of disease rarity, this case was included in aggregated analyses.ResultsA 45-year-old man developed a severe subacute cerebellar syndrome with cognitive, psychiatric, pyramidal, and parkinsonian features. The peak SARA score was 30, and the peak modified Rankin Scale (mRS) score was 5. Despite sequential immunotherapy, only mild improvement occurred and substantial disability persisted. Longitudinal MRI volumetry demonstrated progressive cerebellar atrophy relative to healthy controls, while whole-brain and subcortical volumes remained within normal range. The systematic review identified 21 previously reported patients, yielding 22 including the current case. Cerebellar syndrome was present in all patients; cognitive symptoms were reported in 14 of 22 (64%), parkinsonism in 8 of 22 (36%), and psychiatric symptoms in 6 of 22 (27%). Cerebellar atrophy was reported in 19 of 22 (86%). Two patients had temporally associated tumors. CSF pleocytosis was present in 7 of 21 (33%). The median peak SARA score was 27 (interquartile range [IQR] 23–30; n = 7) and improved to 20 (IQR 18–22), whereas the median mRS score remained 4 at both peak disease and follow-up (n = 11). Among 21 patients with outcome data, 2 (9.5%) died of tumor-related complications, 2 (9.5%) deteriorated neurologically, 8 (38.1%) stabilized, and 9 (42.9%) improved.DiscussionAnti-SEZ6L2 syndrome is characterized by severe cerebellar dysfunction frequently accompanied by parkinsonism, cognitive, and psychiatric features. This case demonstrated progressive cerebellar atrophy on longitudinal volumetry despite immunotherapy. Our systematic synthesis highlights that noncerebellar manifestations are common, and that substantial long-term disability often persists despite partial improvement in ataxia severity. Introduction Cerebellar syndromes encompass a broad differential diagnosis, including autoimmune encephalitis and other immune-mediated disorders.1,2 The recognition of neuronal autoantibodies associated with cerebellar syndromes is relatively recent and has progressed more slowly than in other forms of autoimmune encephalitis. It is important to note that for many antibodies identified in this context, a direct pathogenic role has not been established.3 As a result, immune-mediated cerebellar syndromes are likely underdiagnosed,2 despite the importance of timely recognition, given their potential responsiveness to immunotherapy and, in some cases, association with tumors. Anti–seizure-related 6 homolog like 2 protein (SEZ6L2) antibody-associated syndrome represents a rare cause of cerebellar dysfunction, first described in 2014.4 Patients typically present with severe acute or subacute cerebellar symptoms, frequently accompanied by extrapyramidal signs.5 While some MRI studies have identified cerebellar atrophy, others have reported normal imaging findings.6-9 Likewise, CSF studies have revealed inconsistent findings, ranging from normal results to elevated cell counts.5 Despite treatment with immunotherapy, reported outcomes are generally poor.5 A comprehensive and systematic analysis of anti-SEZ6L2 syndrome is currently lacking.5 In this study, we report the case of a 45-year-old man with anti-SEZ6L2 syndrome. Our analyses included serial clinical assessments, serologic and CSF analyses, immunofluorescence studies, and cross-sectional and longitudinal brain volumetry. In addition, we performed a systematic literature review to synthesize current evidence regarding clinical spectrum, diagnostic features, treatment strategies, and outcomes of anti-SEZ6L2 syndrome. Methods Case Report Standard Protocol Approvals, Registrations, and Patient Consents This case report was prepared in accordance with the CAse Report (CARE) guidelines.10 The retrospective analysis and publication of this case were approved by the research ethics board of Charité–Universitätsmedizin Berlin, Germany (EA4/011/19). Written informed consent for participation in research and for publication was obtained from the participant. Authorization has also been obtained for disclosure (consent to disclose) of any potentially identifiable information (e.g., MRI) or materials that may be published in the journal, in derivative works by the American Academy of Neurology, or on the journal's website. No experiments involving human participants were performed beyond standard clinical care, no experiments on live vertebrates or higher invertebrates were conducted, and this report does not involve a clinical trial or trial registration. Study Visits Clinical symptoms, diagnostic findings, and outcome parameters during initial hospitalization in July-August 2023 were assessed as part of clinical routine. Further diagnostic features and longitudinal outcome were assessed prospectively in 2 study visits: 7 months (study visit 1) and 13 months (study visit 2) after symptom onset. These study visits comprised clinical evaluation, laboratory workup, and MRI studies. Levels of neurofilament light chain (NfL) were measured using the SIMOA method.11 All clinical assessments were conducted by the same neurologist (J.L.H.). General symptom severity was assessed using the modified Rankin Scale (mRS) and the Clinical Assessment Scale in Autoimmune Encephalitis (CASE). Ataxia severity was assessed using the Scale for the Assessment and Rating of Ataxia (SARA; range 0–40 points).12 Brain Volumetry MRI data were acquired on a 1.5T scanner (first clinical MRI) and a 3T scanner (study visits) at Charité—Universitätsmedizin Berlin. MRI data of healthy control participants were obtained on comparable 3T scanners at Charité Berlin. Cortical reconstruction and volumetric segmentation were performed using FreeSurfer image analysis software (version 7.4.1), as previously described.13 Processing steps included motion correction and averaging of T1-weighted images, removal of nonbrain tissue using a watershed/surface deformation algorithm,14 Talairach transformation, segmentation of subcortical structures, and cortical parcellation.15,16 FreeSurfer's longitudinal processing stream was used to ensure unbiased within-participant estimates.17 All outputs were visually inspected by 2 researchers (J.L.H. and G.C.) experienced in FreeSurfer-based volumetry. To account for interindividual differences in head and brain size, the residual approach was applied.18 Immunofluorescence Studies Antibody analysis was performed by indirect immunofluorescence testing for anti-SEZ6L2 IgG (reagents from EUROIMMUN, Lübeck, Germany). Serum samples were tested using biochip mosaics of frozen brain sections (rat hippocampus and cerebellum, monkey cerebellum) and transfected SEZ6L2 HEK293 cells, as previously described.19 In addition, indirect immunofluorescence on unfixed murine brain sections was performed according to established protocols to screen for antibodies not included in routine clinical assays.20,21 Systematic Review Protocol and Search Strategy The systematic review followed PRISMA 2020 guidelines and aimed to summarize clinical features, diagnostic findings, treatments, and outcomes in anti-SEZ6L2 syndrome.22 MEDLINE and EMBASE were systematically searched from 1964 to December 1, 2025, using the terms “sez6l2” AND “Seizure Related 6 Homolog Like 2,” complemented by manual reference screening. Duplicate records were removed prior to screening. All published reports of patients with anti-SEZ6L2 antibodies were eligible, including case reports, case series, and letters to the editor. Conference abstracts were excluded. Non-English articles were translated using ChatGPT 4.0 (OpenAI, San Francisco). Titles and abstracts were screened by J.L. Habicht, and full-texts of potentially relevant studies were assessed for eligibility. Data Extraction and Quality Assessment Data were extracted using a standardized form (J.L.H.) and cross-checked (C.F.). Extracted variables included demographics, clinical features, diagnostic findings, treatments, and outcomes. Methodological quality and risk of bias were assessed independently by 2 reviewers (J.L.H., G.C.) using Joanna Briggs Institute tools for case reports and case series,23 with disagreements resolved by consensus or third-party adjudication (C.F.) Data Synthesis Data were synthesized descriptively because of heterogeneity. Given the rarity of the disease, this case was included in the aggregated analyses. Descriptive statistics were calculated in R (version 4.4.2) and used to summarize demographics, symptom prevalence, tumor association, immunotherapies, and outcomes, including neurologic deterioration, stabilization, improvement, and death, as well as available mRS and SARA scores. Statistical Analysis Summary statistics were calculated and visualized using R (version 4.4.2) and ggplot2. Based on Shapiro-Wilk testing, Q-Q plots, and histograms, volumetric data of healthy controls approximated normal distribution. For each brain structure, mean and SD were calculated from controls, and z-scores were derived for the acute phase and follow-up visits (visit 1 and visit 2). Analyses were implemented using custom-written R code. Data Availability Anonymized data not published within this article will be made available by request from any qualified investigator. Results Case Report Clinical Findings and Volumetric Analysis A 45-year-old man presented with a 2-month history of progressive gait disturbance, dysphagia, 15-kg weight loss, and depressed mood. Neurologic examination revealed a severe cerebellar syndrome, leaving him bedridden at presentation. Additional findings included parkinsonism, pyramidal signs, sporadic involuntary movements, hemifacial spasm, psychomotor slowing, executive dysfunction, and agitation. Initial scores indicated severe disability (SARA 30, CASE 7, mRS 5; Figure 1). Time Line of Events in a Patient With Anti-SEZ6L2 Syndrome The diagram spans symptom onset to last follow-up. Important clinical and diagnostic findings are shown in gray boxes. Blue circles (variable diameter) indicate cerebellar symptom severity (SARA score); diameter at symptom onset is not scaled because no score was yet available. Immunotherapy is shown in blue boxes and pharmaceutical treatment in green boxes. Clinical scores demonstrate partial improvement in cerebellar symptoms and CSF biomarkers after sequential immunotherapy, yet marked disability persisted. Serial MRI showed progressive cerebellar atrophy, and antipsychotics were required for agitation. Ab = antibody; IVMP = intravenous methylprednisolone; mRS = modified Rankin Scale; NfL = neurofilament light chain; PLEX = plasmapheresis; RTX = rituximab; SARA = Scale for the Assessment and Rating of Ataxia. Initial routine brain/spinal MRI, whole-body 18F-FDG-PET/CT, and CT were unremarkable. EEG showed generalized slowing. CSF analysis showed mild pleocytosis (5/µL) and elevated protein (483 mg/L) without oligoclonal bands. NfL was markedly elevated in CSF (9066 pg/mL) and serum (39.1 pg/mL), indicating substantial neuroaxonal damage. Immunofluorescence screening on unfixed mouse brain revealed neuropil staining in the cerebellum together with labeling of Purkinje cells (eFigure 1). A cell-based assay identified anti-SEZ6L2 autoantibodies, and the characteristic binding pattern was confirmed in rat and monkey cerebellum and hippocampus, establishing the diagnosis of anti-SEZ6L2 syndrome. IgG subclass testing was not available. Treatment included IV methylprednisolone, plasmapheresis, and rituximab. After neurorehabilitation, cerebellar symptoms improved only slightly (SARA 27 at 7 months and 25 at 13 months), with mRS score improving to 4; however, the patient remained unable to walk independently or return to work. Psychiatric symptoms required treatment with lorazepam, melperone, and later lithium for emotional lability. At 13-month follow up, CSF cell count and protein had normalized. Antibodies were undetectable, and NfL levels in serum and CSF decreased. Cross-sectional and longitudinal brain volumetric analyses revealed progressive cerebellar atrophy while whole-brain and subcortical volumes remained preserved (Figure 2). Follow-up MRI scans also demonstrated an increasing number of nonspecific white matter lesions. Brain Volumetry in Anti-SEZ6L2 Syndrome Indicates Progressive Cerebellar Atrophy (A) Boxplots showing cross-sectional and longitudinal volumetric data of various brain regions indicate a targeted cerebellar volume loss in anti-SEZ6L2 syndrome, as opposed to whole-brain or subcortical structures. Controls were age-matched and sex-matched healthy individuals. (B) Negative z-scores of cerebellar volumes for the patient with anti-SEZ6L2 syndrome during the acute phase (clinical MRI) and at study visits 1 (7 months of follow-up) and 2 (13 months of follow-up) indicate a progressive and substantial deviation in cerebellar volume, despite neurologic stabilization and the absence of detectable antibodies in CSF and serum during immunotherapy with rituximab. (C) Sequential MRI scans of a patient with anti-SEZ6L2 syndrome demonstrate progressive cerebellar atrophy (arrow). Systematic Literature Review The search yielded 21 previously published cases of anti-SEZ6L2 syndrome, in addition to this case (total n = 22; Figure 3). These cases were reported in 14 articles, including 9 letters to the editors, and the evidence level was uniformly low (JBI Level of Evidence 4). Flow Diagram for Systematic Review Regarding Anti-SEZ6L2 Syndrome Adapted PRISMA 2020 flow diagram showing the identification, screening, and inclusion of studies related to anti-SEZ6L2 syndrome. Clinical, diagnostic, therapeutic, and outcome data were heterogeneous. Summary statistics are provided in Table 1, and detailed patient-level data are presented in eTable 1. TableClinical Characteristics and Outcomes of Patients With Anti-SEZ6L2 Syndrome (n = 22)CharacteristicSummary statistic Demographics Age (y), median (IQR), range57.5 (53–65.5), range 35–73Sex (female)13/20 (65%)Follow-up time (mo), median (IQR)13 (10–20) Clinical symptoms Cerebellar syndrome22/22 (100%) Cognitive symptoms14/22 (64%) Parkinsonism8/22 (36%) Psychiatric symptoms6/22 (27%) Imaging findings Cerebellar atrophy19/22 (86%) Global brain atrophy2/22 (9%) Hippocampus/mesiotemporal atrophy4/22 (18%) Hippocampus T2 hyperintensity (MRI)1/22 (5%) White matter T2 hyperintensities (MRI)3/22 (14%) Tumor detection using PET-CTa2/13 (15%) Laboratory findings CSF pleocytosis7/21 (33%) CSF protein elevation5/16 (31%) CSF OCB positive2/14 (14%) Treatment Time to immunotherapy (mo), median (IQR)4 (2.5–7) Intravenous methylprednisolone18/21 (86%) Intravenous immunoglobulins15/21 (71%) Plasmapheresis/exchange4/21 (19%) Rituximab6/21 (29%) Cyclophosphamide4/21 (19%) Other immunotherapy4/21 (19%) Tacrolimus2/21 (10%) Mycophenolate mofetil2/21 (10%) Efgartigimod1/21 (5%) Outcome Clinical outcome Death (tumor related)2/21 (9.5%) Neurologic deterioration2/21 (9.5%) Neurologic stabilization8/21 (38.1%) Neurologic improvement9/21 (42.9%) Peak disease mRS score, median (IQR)4 (4–5) Outcome mRS score, median (IQR)4 (3–4) Peak disease SARA score, median (IQR)27 (23–30) Outcome SARA score, median (IQR)20 (18–22)Abbreviations: mRS = modified Rankin Scale; SARA = Scale for the Assessment and Rating of Ataxia.Continuous variables are reported as median with interquartile range (IQR) because of the small sample size and non-normal distributions. The number of patients (n) reflects those with available data for the respective variable. mRS and SARA scores were available for 11 and 7 of 22 patients, respectively; in one additional patient, only the peak mRS score was reported without follow-up outcome data. Four patients had both mRS and SARA scores available. Some patients presented with multiple MRI abnormalities and preexisting conditions. Data on time to immunotherapy were available for 19 of 22 patients.aOne additional patient developed ovarian cancer 4 years after the diagnosis of anti-SEZ6L2 syndrome, making a causal association unlikely. Clinical Characteristics and Outcomes of Patients With Anti-SEZ6L2 Syndrome (n = 22) Abbreviations: mRS = modified Rankin Scale; SARA = Scale for the Assessment and Rating of Ataxia. Continuous variables are reported as median with interquartile range (IQR) because of the small sample size and non-normal distributions. The number of patients (n) reflects those with available data for the respective variable. mRS and SARA scores were available for 11 and 7 of 22 patients, respectively; in one additional patient, only the peak mRS score was reported without follow-up outcome data. Four patients had both mRS and SARA scores available. Some patients presented with multiple MRI abnormalities and preexisting conditions. Data on time to immunotherapy were available for 19 of 22 patients. One additional patient developed ovarian cancer 4 years after the diagnosis of anti-SEZ6L2 syndrome, making a causal association unlikely. The median age at symptom onset was 57.5 years, and 65% were women. Autoimmune comorbidities were present in 4 of 17 evaluable patients, including hypothyroidism (n = 2), Crohn disease (n = 1), and membranous nephropathy (n = 1). One patient had longstanding hyponatremia prior to a diagnosis of small-cell lung cancer (SCLC). Two patients (14%) were treated for depressive episodes. All cases presented with cerebellar syndrome. Further symptoms included cognitive impairment (63%), parkinsonism (36%), psychiatric symptoms (27%), and pyramidal signs (23%) (Figure 4). Less-frequent features were aphasia (9%), involuntary limb movements (9%), nausea (9%), weight loss (9%), autonomic dysfunction (9%), apraxia (5%), muscle weakness (5%), headache (5%), and visual impairment due to retinopathy (5%). Clinical Phenotype and Outcome in Anti-SEZ6L2 Syndrome (A) Symptom prevalence at peak disease (n = 22). Left polar plot shows the 5 principal clinical domains—cerebellar (universal), cognitive, psychiatric, parkinsonism, and other symptoms. Right polar plot visualizes the frequency of less common manifestations. (B) Clinical scores. Paired bar plots show the Scale for the Assessment and Rating of Ataxia (SARA; n = 7) and modified Rankin Scale (mRS; n = 11) at peak disease vs last available follow-up. The median SARA score improved by 8 points, whereas the median mRS score did not improve, indicating persistent global disability despite amelioration of cerebellar symptoms. For 2 patients who later died of tumor-related complications, the last mRS score recorded before death was used. Both scores were available for 4 individuals. (C) Categorical long-term outcome (n = 21). Because scale scores were incomplete, patients were assigned to 4 broad outcome categories: tumor-related death in 2 patients (9.5%), neurologic deterioration in 2 (9.5%), stabilization in 8 (38.1%), and improvement in 9 (42.9%). One additional patient lacked follow-up data and is not shown in the bar plot. Percentages are calculated relative to the number of patients with available outcome information. mRS = modified Rankin Scale; SARA = Scale for the Assessment and Rating of Ataxia. MRI revealed cerebellar atrophy in 19 of 22 cases (86%). Other MRI abnormalities included global brain atrophy including the hippocampus/medial temporal lobes in 4 patients. One patient with additional serum GABA-B-R antibodies showed hippocampal T2 hyperintensity. Further brain imaging studies (PET, SPECT, scintigraphy, DaTScan) identified abnormalities in 4 of 11 patients (36%), showing cerebellar hypometabolism or hypoperfusion. DaTScans were negative in 2 patients tested (0/2). Temporally associated tumors were detected in 2 patients by PET/CT imaging (SCLC; breast cancer), and one additional patient developed ovarian cancer 4 years after neurologic onset. The patients with SCLC and ovarian cancer died of tumor progression, whereas the patient with breast carcinoma improved neurologically after tumor treatment. CSF pleocytosis was reported in approximately one-third, protein elevation in 31%, and oligoclonal bands (OCBs) were positive in 14%. Serum anti-SEZ6L2 autoantibody titers (median 1:200, interquartile range [IQR] 1:200–1:1,000) exceeded CSF titers (median 1:5, IQR 1:5–1:32) in 11 of 12 cases with paired samples (92%). One patient had additional serum anti–GABA-B-R. Markers of neuroaxonal injury (NfL and/or tau) were abnormal in 4 of 5 tested cases. Most patients received IV methylprednisolone (86%) and/or IVIG (71%), with some also treated with plasma exchange (19%), rituximab (29%), and cyclophosphamide (19%). Less common immunotherapies included tacrolimus (10%) and mycophenolate mofetil (10%), and efgartigimod (5%). The median time to immunotherapy was 4 months. Among 21 patients with available follow-up data, 2 patients died of tumor-related complications, 2 deteriorated neurologically, 8 stabilized, and 9 improved. Available scores indicated marked cerebellar dysfunction (median SARA score 27, IQR 23–30) and substantial disability (median mRS score 4, IQR 4–5) at peak disease. Although treatment led to improvement in cerebellar symptoms (median outcome SARA score 20, IQR 18–22), substantial disability persisted (median outcome mRS 4, IQR 3–4). Only total SARA scores were available, so no conclusions can be drawn about individual item performance. Discussion This case illustrates the clinical phenotype of anti-SEZ6L2 syndrome characterized by a severe cerebellar syndrome accompanied by cognitive dysfunction, parkinsonism, and psychiatric manifestations. Sequential immunotherapy led to antibody clearance and marked improvement in CSF and serum NfL, but only limited functional recovery, consistent with the poor overall outcomes observed across published cases. The case also underscores the clinical relevance of psychiatric manifestations, which required repeated psychopharmacologic treatment. Given the severity of his dysarthria, the patient's perspective could not be reliably assessed; caregivers reported that emotional lability and loss of independence appeared most burdensome. Immunofluorescence studies showed the characteristic anti-SEZ6L2 staining pattern and supported diagnostic confirmation. Longitudinal quantitative brain volumetry demonstrated progressive cerebellar atrophy despite immunotherapy and despite preservation of whole-brain and subcortical volumes. This selective cerebellar volume loss is notable, given the broader expression of SEZ6L2 in extracerebellar regions.24 A limitation of the case report is that severe dysarthria and a language barrier precluded formal neuropsychological testing and may have led to underestimation of cognitive deficits. In the aggregated cohort of 22 patients, the median age at onset was approximately 58 years and women predominated among evaluable cases. Cerebellar syndrome was universal, but additional symptoms were frequent and included cognitive deficits, parkinsonism, psychiatric manifestations, and pyramidal signs. Less common features were aphasia, nausea, weight loss, and autonomic dysfunction. One patient exhibited visual disturbances due to retinopathy,4 an interesting finding, given the expression of SEZ6L2 in the human retina.25 While cerebellar syndrome and parkinsonism have been previously recognized as key features of anti-SEZ6L2 syndrome, our findings emphasize the relevance of cognitive impairment and psychiatric symptoms. These manifestations may reflect the cerebellar cognitive affective syndrome (CCAS; Schmahmann syndrome), a recognized consequence of cerebellar pathology.26,27 Cognitive deficits in CCAS typically involve executive dysfunction, attentional impairments, and language production difficulties, while the affective component frequently encompasses emotional dysregulation (e.g., impulsivity, anxiety, agitation, and depression). Indeed, these CCAS-associated cognitive symptoms were frequently reported in patients with SEZ6L2 syndrome. Moreover, 3 patients required medication to treat emotional dysregulation, including our patient. CSF was usually noninflammatory, with serum anti-SEZ6L2 antibody titers exceeding CSF titers in 92% of paired samples, and markers of neuroaxonal damage were elevated in most patients. MRI demonstrated cerebellar atrophy in 86%, while functional imaging (PET/SPECT/scintigraphy) revealed cerebellar hypometabolism or hypoperfusion in approximately one-third of studied cases and may prove helpful when initial MRI findings are unremarkable. Relevant comorbidities included autoimmune diseases in 4 patients and temporally associated tumors in 2 patients, detected at presentation by whole-body PET/CT (small-cell lung cancer and breast cancer). By contrast, metastatic ovarian cancer was diagnosed in another patient 4 years after the onset of anti-SEZ6L2–associated syndrome, making a causal association less likely. Most patients received first-line immunotherapy with corticosteroids and/or IVIG; plasma exchange was administered in approximately 20%, with escalation to rituximab or cyclophosphamide in one-third of cases. Despite treatment, outcomes were often unsatisfactory. Although SARA scores improved where available, median mRS scores remained unchanged, indicating persistent global disability. In addition, 2 patients deteriorated despite treatment and 2 died of tumor-related complications. By contrast, 4 female patients demonstrated substantial clinical improvement with immunotherapy. Significant clinical improvement was also reported in a patient with breast cancer after tumor therapy. These cases highlight the potential benefit of aggressive immunotherapy and, when appropriate, tumor therapy. The pathophysiology of anti-SEZ6L2 syndrome remains incompletely understood. Prior work suggests that anti-SEZ6L2 antibodies may interfere with AMPA receptor–related signaling and cathepsin D trafficking.5,24,28 Although anti-SEZ6L2 antibodies do not induce antigen internalization, they might exert pathogenic effects via the IgG4 subclass—which was predominant in 5 of 8 reported cases—by interfering with the interaction between SEZ6L2 and the GluA1 subunit of the AMPA receptor.9,29,30 This disruption impairs synaptic transmission, potentially contributing to cerebellar dysfunction.24 Recent experimental work further suggests that SEZ6L2 autoimmunity may involve both antibody-mediated neuronal injury and T-cell–driven neuroinflammation.31 In a mouse model, immunization with SEZ6L2 induced motor impairment accompanied by cerebellar IgG deposition, reactive microglia, and infiltration of SEZ6L2-specific CD4+ T cells, supporting a multifaceted immune-mediated mechanism of cerebellar injury.31 The overall poor outcomes in anti-SEZ6L2 syndrome may be attributed to the loss of Purkinje cells in the cerebellum, a phenomenon similarly described in paraneoplastic cerebellar degeneration (PCD) associated with anti-P/Q-type voltage-gated calcium channel (P/Q-VGCC) antibodies.9,32 The CCAS alone may account for the cognitive and psychiatric manifestations in anti-SEZ6L2 syndrome,27 which is consistent with the absence of extracerebellar atrophy in our patient. However, additional pathophysiologic mechanisms may be involved.33,34 SEZ6L2 is richly expressed in neocortical and limbic regions—including the amygdala, hippocampus, and striatum—and immunofluorescence studies have demonstrated antibody binding to these structures.9,25,35 Direct disruption of hippocampal and amygdalar circuits may, therefore, contribute to the cognitive and affective disturbances, while striatal involvement offers a plausible explanation for the parkinsonian features seen in many patients. This study is limited by the heterogeneity and low level of evidence of available data, which is derived exclusively from case reports and small case series. Furthermore, most data were collected retrospectively, with clinical scales and outcome measures inconsistently reported across studies, limiting direct comparisons. Given the study's design, all findings should be considered exploratory and descriptive. Anti-SEZ6L2 syndrome typically presents with a subacute cerebellar syndrome accompanied by additional symptoms, including cognitive symptoms, parkinsonism, and psychiatric manifestations. Prompt immunotherapy combined with a systematic tumor search including whole-body PET/CT is recommended. Nevertheless, long-term disability remains frequent, and reliable predictors of treatment response have yet to be identified.